WHI-P 154

Key Product Details

Product Description

WHI-P 154 is a JAK3 inhibitor (IC₅₀ = 1.8 μM) that displays no activity at JAK1 or JAK2. Inhibits STAT1 activation, iNOS expression and NO production in macrophages in vitro. Also inhibits other common kinases including EGFR (IC₅₀ = 4 nM), Src, Abl, VEGFR, MAPK and PI 3-K and induces apoptosis in human glioblastoma cell lines (IC₅₀ = 158 μM). Induces differentiation of neural progenitor cells.

Product Specifications for WHI-P 154

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for WHI-P 154

The following data is based on the product molecular weight 376.20.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.66 mL	13.29 mL	26.58 mL
5 mM	0.53 mL	2.66 mL	5.32 mL
10 mM	0.27 mL	1.33 mL	2.66 mL
50 mM	0.05 mL	0.27 mL	0.53 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Kim Differential regulation of proliferation and differentiation in neural precursor cells by the Jak pathway. Stem Cells. 2010 PMID: 20979137
• Sareila Janus kinase 3 inhibitor WHI-P154 in macrophages activated by bacterial endotoxin: differential effects on the expression of iNOS, COX-2 and TNF-α. Int.Immunopharmacol. 2008 PMID: 18068105
• Changelian The specificity of JAK3 kinase inhibitors. Blood 2008 PMID: 18094329
• Narla 4-(3'-bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin.Cancer Res. 1998 PMID: 9626456

Product Documents for WHI-P 154